Latest filings (excl ownership)
D
$50.00 mm in equity / options / securities to be acquired, sold $50.00 mm, 25 investors
20 Mar 24
8-K
Unicycive Announces $50 Million Private Placement
14 Mar 24
8-K
Entry into a Material Definitive Agreement
14 Mar 24
8-K
Other Events
21 Feb 24
S-8
Registration of securities for employees
8 Dec 23
8-K
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
14 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Other Events
23 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
25 Sep 23
8-K
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
6 Sep 23
8-K
Changes in Registrant's Certifying Accountant
31 Aug 23
8-K
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
EFFECT
Notice of effectiveness
4 Aug 23
CORRESP
Correspondence with SEC
1 Aug 23
8-K
Changes in Registrant's Certifying Accountant
31 Jul 23
8-K
Other Events
26 Jul 23
UPLOAD
Letter from SEC
19 Jul 23
S-3
Shelf registration
12 Jul 23
8-K
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
29 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
26 Jun 23
DEFA14A
Additional proxy soliciting materials
12 Jun 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 May 23
8-K
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
16 May 23
10-Q
2023 Q1
Quarterly report
16 May 23
NT 10-Q
Notice of late quarterly filing
16 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
PRE 14A
Preliminary proxy
18 Apr 23
8-K
Entry into a Material Definitive Agreement
10 Apr 23
8-K
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
31 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Other Events
30 Mar 23
D
$30.19 mm in equity / options / securities to be acquired, sold $30.19 mm, 20 investors
13 Mar 23
8-K
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
6 Mar 23
8-K
Other Events
2 Mar 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Feb 23
8-K
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
2 Feb 23
8-K
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
29 Dec 22
Latest ownership filings
SC 13G/A
RA CAPITAL MANAGEMENT, L.P.
14 Feb 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G
Nantahala Capital Partners Limited Partnership
5 Feb 24
SC 13G
Logos Global Management LP
22 Jan 24
4
Sandeep Laumas
7 Sep 23
4
Sara Kenkare-Mitra
7 Sep 23
4
John L Ryan
7 Sep 23
4
Gaurav Aggarwal
7 Sep 23
3
Sara Kenkare-Mitra
7 Sep 23
4
Pramod Gupta
30 Aug 23
4
Shalabh K. Gupta
30 Aug 23
4
John Townsend
30 Aug 23
4
Douglas Jermasek
30 Aug 23
SC 13G
Vivo Opportunity Fund Holdings, L.P.
14 Jul 23
4
Gaurav Aggarwal
13 Jul 23
4
Douglas Jermasek
13 Jul 23
4
Pramod Gupta
13 Jul 23
4
Shalabh K. Gupta
13 Jul 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
6 Jul 23
SC 13G
RA CAPITAL MANAGEMENT, L.P.
6 Jul 23
4/A
Brigitte Schiller
18 Apr 23
4
Gaurav Aggarwal
9 Mar 23
4
Shalabh K. Gupta
9 Mar 23
4
Pramod Gupta
9 Mar 23
4
Douglas Jermasek
9 Mar 23
3
Gaurav Aggarwal
8 Mar 23
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 23
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 23
4
John Townsend
23 Nov 22
4
Douglas Jermasek
23 Nov 22
4
Shalabh K. Gupta
23 Nov 22
4
Pramod Gupta
23 Nov 22
3
Douglas Jermasek
21 Nov 22
4
Brigitte Schiller
30 Aug 22
4
Brigitte Schiller
17 May 22
SC 13G
ARMISTICE CAPITAL, LLC
15 Feb 22
SC 13G
Nantahala Capital Management, LLC
14 Feb 22
SC 13G/A
Altium Capital Management LP
14 Feb 22
SC 13G/A
Rosalind Advisors, Inc.
20 Jan 22